What is Orilissa (elagolix) and how is it used?
Orilissa is a prescription medicine used to treat moderate to severe pain associated with endometriosis. It is not known if
Orilissa is safe and effective in children under 18 years of age.
What are the side effects of Orilissa?
Orilissa may cause serious side effects, including:
- bone loss (decreased bone mineral density).
- While you are taking
Orilissa, your estrogen levels will be low. Low estrogen levels can lead to bone mineral density loss. - Your bone density may improve after you stop taking
Orilissa but complete recovery may not occur. It is unknown if these bone changes could increase your risk for broken bones as you age. - Your healthcare provider may advise you to take vitamin D and calcium supplements as part of a healthy lifestyle that promotes bone health.
- If you have conditions or take other medicines that can cause bone loss, or if you have broken a bone with minimal or no injury, your healthcare provider may order an X-ray test called a DXA scan to check your bone mineral density.
- While you are taking
- suicidal thoughts, suicidal behavior, and worsening of mood.
Orilissa may cause suicidal thoughts or actions. Call your healthcare provider right away if you have any of these symptoms or call 911 if an emergency, especially if they are new, worse, or bother you:- thoughts about suicide or dying
- try to commit suicide
- new or worse depression
- new or worse anxiety
- other unusual changes in behavior or mood
- abnormal liver tests. Call your healthcare provider right away if you have any of these signs and symptoms of liver problems:
- Take Orilissa exactly as your healthcare provider tells you to take it.
- Your healthcare provider will give you a pregnancy test before you start taking
Orilissa or will have you start taking Orilissa within 7 days after you start your period.- If your healthcare provider prescribes:
Orilissa 150 mg (a pink tablet), take it 1 time each day - Orilissa 200 mg (an orange tablet), take it 2 times each day
- If your healthcare provider prescribes:
- Take
Orilissa at about the same time each day with or without food. - If you miss a dose of
Orilissa:- 150 mg (1 time each day), take it as soon as you remember as long as it is on the same day. Do not take more than 1 tablet each day.
- 200 mg (2 times each day), take it as soon as you remember as long as it is on the same day. Do not take more than 2 tablets each day.
- If you take too much
Orilissa, call your healthcare provider or go to the nearest hospital.
- Urinary Incontinence Affect Woman’s Mental Health
- Take These Key Steps to Good Urological Health
- Fibroid Pain, Bleeding Is Driving Thousands to ER
- Mammography Rates Plummeted During Pandemic
- Obesity May Help Trigger Heavier Periods: Study
- Want More News? Sign Up for MedicineNet Newsletters!
- H5N6 Bird Flu Infection in China
- COVID Vaccine Misinformation
- Antibiotic-Resistant Pneumonia
- Mask Mandate Returns to L.A.
- Fermented Foods Help Microbiome
More Health News »- Guillain-Barre Syndrome
- What Triggers Shingles?
- Normal Blood Sugar Levels
- Identify Tick Bites
- Why Is Autism Increasing?
Orilissa can cause serious side effects including:
You or your caregiver should pay attention to any changes, especially sudden changes in your mood, behaviors, thoughts, or feelings.
The most common side effects of
Orilissa include: hot flashes or night sweats, headache, nausea, difficulty sleeping, absence of periods, anxiety, joint pain, depression and mood changes.
These are not all the possible side effects of
Orilissa. Call your healthcare provider for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088.
What is the dosage of Orilissa?
What drugs interact with Orilissa?
Elagolix is a weak to moderate inducer of cytochrome P450 (CYP) 3A. Co-administration with
Orilissa may decrease plasma concentrations of drugs that are substrates of CYP3A.
Elagolix is a weak inhibitor of CYP 2C19. Co-administration with
Orilissa may increase plasma concentrations of drugs that are substrates of CYP2C19 (e.g., omeprazole).
Elagolix is an inhibitor of efflux transporter P-glycoprotein (P-gp). Co-administration with
Orilissa may increase plasma concentrations of drugs that are substrates of P-gp (e.g., digoxin).
Potential For Other Drugs To Affect Orilissa
Elagolix is a substrate of CYP3A, P-gp, and OATP1B1.
Concomitant use of
Orilissa 200 mg twice daily and strong CYP3A inhibitors for more than 1 month is not recommended. Limit concomitant use of
Orilissa 150 mg once daily and strong CYP3A inhibitors to 6 months.
Co-administration of
Orilissa with drugs that induce CYP3A may decrease elagolix plasma concentrations.
The effect of concomitant use of P-gp inhibitors or inducers on the pharmacokinetics of
Orilissa is unknown. Co-administration of Orilissa with drugs that inhibit OATP1B1 may increase elagolix plasma concentrations. Concomitant use of
Orilissa and strong OATP1B1 inhibitors (e.g., cyclosporine and gemfibrozil) is contraindicated.
Drug Interactions-Examples And Clinical Management
Table 7 summarizes the effect of co-administration of
Orilissa on concentrations of concomitant drugs and the effect of concomitant drugs on
Orilissa.
Table 7. Established Drug Interactions Based on Drug Interaction Trials
Concomitant DrugClass:
Drug NameEffect on Plasma Exposure of Elagolix or Concomitant DrugClinical RecommendationsAntiarrhythmics
digoxin↑ digoxinClinical monitoring is recommended for digoxin when co-administered with
Orilissa.Antimycobacterial
rifampin↑ elagolixConcomitant use of
Orilissa 200 mg twice daily and rifampin is not recommended. Limit concomitant use of
Orilissa 150 mg once daily and rifampin to 6 months.Benzodiazepines
oral midazolam↓ midazolamConsider increasing the dose of midazolam and individualize therapy based on the patient’s response.Statins
rosuvastatin↓ rosuvastatinConsider increasing the dose of rosuvastatin.Proton pump inhibitors
omeprazole↑ omeprazoleNo dose adjustments are needed for omeprazole at doses of 40 mg once daily or lower. When
Orilissa is used concomitantly with higher doses of omeprazole, e.g. in patients with Zollinger-Ellison syndrome, consider dosage reduction of omeprazole.The direction of the arrow indicates the direction of the change in the area under the curve (AUC) (↑= increase, ↓ = decrease).
Latest Women’s Health News
Daily Health News
Trending on MedicineNet
Is Orilissa safe to take while pregnant or breastfeeding?
Do not take Orilissa if you are trying to become or are pregnant. It may increase the risk of early pregnancy loss. If you think you are pregnant, stop taking
Orilissa right away and call your healthcare provider.
If you become pregnant while taking
Orilissa, you are encouraged to enroll in the Pregnancy Registry. The purpose of the pregnancy registry is to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-833-782-7241to enroll in this registry.
Orilissa may change your menstrual periods (irregular bleeding or spotting, a decrease in menstrual bleeding, or no bleeding at all), making it hard to know if you are pregnant. Watch for other signs of pregnancy such as breast tenderness, weight gain and nausea.
Orilissa does not prevent pregnancy. You will need to use effective methods of birth control that do not contain hormones such as condoms or spermicide while taking
Orilissa and for 1 week after you stop taking Orilissa. Birth control pills that contain estrogen may make
Orilissa less effective. It is not known how well Orilissa will work while you are taking progestin-only birth control such as injections or implants.
Talk to your healthcare provider about which birth control to use during treatment with
Orilissa. Your healthcare provider may change the birth control you were on before you start taking
Orilissa.
Do not take Orilissa if you are breastfeeding or plan to breastfeed. It is not known if
Orilissa passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby if you take
Orilissa.